Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals.
Hepatocellular Carcinoma
DRUG: TACE combined with Camrelizumab|PROCEDURE: TACE plus Camrelizumab
Progression Free Survival, the time from enrollment to the first disease progression or death from any cause, an expected average of 8 months
Time to progression, the time from enrollment to the first disease progression, An expected average of 8 months|Overall survival, the time from enrollment to the death from any cause, An expected average of 24 months|Objective response rate, evaluated by investigators with mRECIST, An expected average of 8 months|Disease control rate, evaluated by investigators with mRECIST, An expected average of 8 months|Duration of response, evaluated by investigators with mRECIST, An expected average of 8 months|The incidence of AEs and SAEs by NCI-CTCAE v5.0, Safety index, An expected average of 8 months
This is a prospective, single-center and single-arm exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C hepatocellular carcinoma.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals.